276 related articles for article (PubMed ID: 33337513)
1. Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression.
D'Agate S; Chavan C; Manyak M; Palacios-Moreno JM; Oelke M; Michel MC; Roehrborn CG; Della Pasqua O
World J Urol; 2021 Jul; 39(7):2635-2643. PubMed ID: 33337513
[TBL] [Abstract][Full Text] [Related]
2. Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH.
D'Agate S; Wilson T; Adalig B; Manyak M; Palacios-Moreno JM; Chavan C; Oelke M; Roehrborn C; Della Pasqua O
World J Urol; 2020 Feb; 38(2):463-472. PubMed ID: 31079189
[TBL] [Abstract][Full Text] [Related]
3. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
5. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.
Zhou Z; Cui Y; Wu J; Ding R; Cai T; Gao Z
BMC Urol; 2019 Mar; 19(1):17. PubMed ID: 30871552
[TBL] [Abstract][Full Text] [Related]
7. Model-based meta-analysis of the time to first acute urinary retention or benign prostatic hyperplasia-related surgery in patients with moderate or severe symptoms.
D'Agate S; Chavan C; Manyak M; Palacios-Moreno JM; Oelke M; Michel MC; Roehrborn CG; Della Pasqua O
Br J Clin Pharmacol; 2021 Jul; 87(7):2777-2789. PubMed ID: 33247951
[TBL] [Abstract][Full Text] [Related]
8. Superiority of dutasteride 0.5 mg and tamsulosin 0.2 mg for the treatment of moderate-to-severe benign prostatic hyperplasia in Asian men.
Haque N; Masumori N; Sakamoto S; Ye Z; Yoon SJ; Kuo HC; Brotherton B; Wilson T; Muganurmath C; McLaughlin M; Manyak M
Int J Urol; 2018 Nov; 25(11):944-951. PubMed ID: 30198102
[TBL] [Abstract][Full Text] [Related]
9. Understanding Treatment Response in Individual Profiles of Men with Prostatic Enlargement at Risk of Progression.
Gravas S; Palacios-Moreno JM; Thompson D; Concas F; Kamola PJ; Roehrborn CG; Oelke M; Kattan MW; Averbeck MA; Manyak M; Cortés V; Lulic Z
Eur Urol Focus; 2023 Jan; 9(1):178-187. PubMed ID: 35985933
[TBL] [Abstract][Full Text] [Related]
10. Dutasteride/tamsulosin: in benign prostatic hyperplasia.
Keating GM
Drugs Aging; 2012 May; 29(5):405-19. PubMed ID: 22550968
[TBL] [Abstract][Full Text] [Related]
11. The effects of combination therapy with dutasteride plus tamsulosin on clinical outcomes in men with symptomatic BPH: 4-year post hoc analysis of European men in the CombAT study.
Haillot O; Fraga A; Maciukiewicz P; Pushkar D; Tammela T; Höfner K; Chantada V; Gagnier P; Morrill B
Prostate Cancer Prostatic Dis; 2011 Dec; 14(4):302-6. PubMed ID: 21502969
[TBL] [Abstract][Full Text] [Related]
12. Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database.
Lulic Z; Son H; Yoo SB; Cunnington M; Kapse P; Miller D; Cortes V; Park S; Bhak RH; Duh MS
BMC Urol; 2021 Dec; 21(1):178. PubMed ID: 34933674
[TBL] [Abstract][Full Text] [Related]
13. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
[TBL] [Abstract][Full Text] [Related]
14. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
[TBL] [Abstract][Full Text] [Related]
15. Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study.
Oelke M; Roehrborn CG; D'Ancona C; Wilson TH; Castro R; Manyak M
World J Urol; 2014 Oct; 32(5):1133-40. PubMed ID: 24804842
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.
Chung BH; Lee SH; Roehrborn CG; Siami PF; Major-Walker K; Wilson TH; Montorsi F;
Int J Urol; 2012 Nov; 19(11):1031-5. PubMed ID: 22774774
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of men with untreated LUTS interested in over-the-counter tamsulosin.
Roehrborn CG; Lowe FC; Gittelman M; Wruck JM; Verbeek AE
Can J Urol; 2019 Aug; 26(4):9821-9828. PubMed ID: 31469636
[TBL] [Abstract][Full Text] [Related]
19. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
[TBL] [Abstract][Full Text] [Related]
20. [Combination drug therapy in patients with BPH].
Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA
Urologiia; 2018 Mar; (1):101-105. PubMed ID: 29634142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
